Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: A comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 4, 2014, Pages 138-154

  Megens, Anton A H P ^a   Hendrickx, Herman M R ^a   Hens, Koen A ^a   Fonteyn, Ineke ^a   Langlois, Xavier ^a   Lenaerts, Ilse ^a   Somers, Marijke V F ^a   De Boer, Peter ^a   Vanhoof, Greet ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE ANTAGONISTS; FEMALE; GUINEA PIGS; HUMANS; IMIDAZOLES; MALE; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROLACTIN; PROTEIN BINDING; PYRAZINES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SF9 CELLS; SPODOPTERA; STEREOTYPED BEHAVIOR;

EID: 84896473357     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211904     Document Type: Article

References (39)

1. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, and Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54: 1205-1213.
2. DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt C, and Arroyo S (2012) Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophr Res 136(Suppl 1):S262.
3. Demjaha A, Murray RM, McGuire PK, Kapur S, and Howes OD (2012) Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169:1203-1210.
4. Dickson RA and Glazer WM (1999) Neuroleptic-induced hyperprolactinemia. Review 81 refs Schizophr Res 35 (Suppl):S75-S86.
5. Dreyer JK, Herrik KF, Berg RW, and Hounsgaard JD (2010) Influence of phasic and tonic dopamine release on receptor activation. J Neurosci 30:14273-14283.
6. Erritzoe D, Talbot P, Frankle WG, and Abi-Dargham A (2003) Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clin N Am 13:817-832.
7. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, and Omori K (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438-18445.
8. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, and Jiang L, et al. (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590.
9. Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244-254.
10. Graybiel AM (2000) The basal ganglia. Curr Biol 10:R509-R511.
11. Hurley MJ and Jenner P (2006) What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 111:715-728.
12. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
13. Kehler J and Kilburn JP (2009) Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Pat 19:1715-1725.
14. Kehler J, Ritzen A, and Greve DR (2007) The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Patents 17:147-158.
15. Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, and Kuhn M, et al. (2011) Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther 336:64-76.
16. Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te Riele P, Peeters L, Wouters R, Vermeire J, and Hendrickx H, et al. (2012) Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 342:91-105.
17. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, and Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72.
18. 50) and its Confidence Interval, Assuming a Linear Log Dose-Response Function. Internal Report N123705/1. Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica, Turnhoutseweg, Beerse, Belgium.
19. Leysen JE (2000) Receptor profile of neuroleptics, in Atypical Antipychotics (Ellenbroek BA and Cools AR, eds) Birkhauser Verlag, Basel, Switzerland.
20. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, and Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234:109-117.
21. Mailman R, Huang X, and Nichols DE (2001) Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs 2:1582-1591.
22. Menniti FS, Chappie TA, Humphrey JM, and Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54-59.
23. Niemegeers CJE and Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201-2216.
24. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, and Greengard P,, et al. (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28: 10460-10471.
25. Sammut S, Threlfell S, and West AR (2010) Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo. Neuropharmacology 58:624-631.
26. Sano H, Nagai Y, Miyakawa T, Shigemoto R, and Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105:546-556.
27. Schmidt CJ (2012) Preclinical characterization of PDE10A inhibitors as putative antipsychotic agents. Biol Psychiatry 71:17S.
28. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, and Nelson FR, et al. (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690.
29. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, and Strick CA, et al. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126.
30. Seeman P (2006) Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531.
31. Siuciak JA (2008) The role of phosphodiesterases in schizophrenia : therapeutic implications. CNS Drugs 22:983-993.
32. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, and Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396.
33. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, and Menniti FS, et al. (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374-385.
34. Soderling SH, Bayuga SJ, and Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071-7076.
35. Sotty F, Montezinho LP, Steiniger-Brach B, and Nielsen J (2009) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766-775.
36. Tsutakawa RK (1982) Statistical methods in bioassay: estimation of relative potency from quantal responses. in Encyclopedia of Statistical Science (Kotz S, Johnson N L, eds), pp 236-243. John Wiley, New York.
37. Uthayathas S, Masilamoni GS, Shaffer CL, Schmidt CJ, Menniti FS, and Papa SM (2014) Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications. Neuropharmacology 77: 257-267.
38. Westfall TC andWestfall DP (2006) Adrenergic agonists and antagonists in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton L, Lazo JS, and Parker K, eds) pp 237-295, McGraw-Hill, Medical Publishing Division, New York.
39. Zhang J, Xiong B, Zhen X, and Zhang A (2009) Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 29:272-294.